Acetazolamide, a carbonic anhydrase inhibitor, reduces cerebrospinal fluid production and intracranial pressure, which may help modulate the neurological mechanisms underlying cluster headaches. By inhibiting carbonic anhydrase enzymes, it alters pH and reduces neurogenic inflammation, potentially disrupting the trigeminovascular pathway and providing prophylactic relief for cluster headache episodes.